bispecific antibody Archives -

Market Access/ News/ News/ News/ Oncology

Roche claims US approval for lymphoma bispecific Lunsumio

Phil Taylor Biogen, bispecific antibody, follicular lymphoma, Lunsumio, non-Hodgkin lymphoma, Oncology, regulatory approval, Roche 0 Comment

The FDA has given a green light to Roche’s CD20xCD3 bispecific antibody Lunsumio as a treatment for relapsed

Roche claims US approval for lymphoma bispecific Lunsumio

https://pharmaphorum.com/news/roche-claims-us-approval-for-lymphoma-bispecific-lunsumio/

News/ News/ News/ Oncology/ R&D

ASH: J&J makes case for just-filed GPRC5D drug talquetamab

Phil Taylor bispecific antibody, GPRC5D, Haematology, Johnson & Johnson, multiple myeloma, Oncology 0 Comment

Johnson & Johnson is in pole position to bring a drug targeting GPRC5D to market as a new

ASH: J&J makes case for just-filed GPRC5D drug talquetamab

https://pharmaphorum.com/news/ash-jj-makes-case-for-just-filed-gprc5d-drug-talquetamab/

News/ News/ News/ Oncology/ R&D

Little Summit Therapeutics spends big bucks to rebuild pipeline

Phil Taylor Akeso, bispecific antibody, immuno-oncology, licensing, Non-small cell lung cancer, Oncology, Summit Therapeutics 0 Comment

$500 million upfront and a total deal value of up to $5 billion sounds like a deal made

Little Summit Therapeutics spends big bucks to rebuild pipeline

https://pharmaphorum.com/news/little-summit-therapeutics-spends-big-bucks-to-rebuild-pipeline/

Market Access/ News/ News/ News/ Oncology

J&J nabs FDA okay for BCMA bispecific Tecvayli

Phil Taylor BCMA, bispecific antibody, Haematology, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology, regulatory approval, Tecvayli 0 Comment

Johnson & Johnson has secured another regulatory approval for its BCMAxCD3 bispecific antibody for multiple myeloma – Tecvayli

J&J nabs FDA okay for BCMA bispecific Tecvayli

https://pharmaphorum.com/news/jj-nabs-fda-okay-for-bcma-bispecific-tecvayli/

News/ News/ News/ Oncology/ R&D

Gilead pledges $1.76bn to MacroGenics for bispecific cancer antibody

Phil Taylor bispecific antibody, Gilead Sciences, Haematology, MacroGenics, Oncology, partnering 0 Comment

Gilead Sciences has made yet another rush into the oncology category, licensing a bispecific antibody from MacroGenics in

Gilead pledges $1.76bn to MacroGenics for bispecific cancer antibody

https://pharmaphorum.com/news/gilead-pledges-1-76bn-to-macrogenics-for-bispecific-cancer-antibody/

Janssen J&J Johnson and Johnson pharmaceutical companies

Market Access/ News/ News/ News/ Oncology

CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision

Phil Taylor bispecific antibody, CHMP, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology, teclistamab, Tecvayli 0 Comment

The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for

CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision

https://pharmaphorum.com/news/chmp-backs-jjs-myeloma-bispecific-tecvayli-ahead-of-us-decision/

News/ News/ Oncology

Roche trumpets new glofitamab data in lymphoma at ASCO

Phil Taylor bispecific antibody, diffuse B-Cell lymphoma, epcoritamab, glofitamab, non-Hodgkin lymphoma, Polivy, Roche 0 Comment

Roche will present the new data at next week’s ASCO congress showing that its bispecific antibody glofitamab can

Roche trumpets new glofitamab data in lymphoma at ASCO

https://pharmaphorum.com/news/roche-trumpets-new-glofitamab-data-in-lymphoma-at-asco/

News/ News/ Oncology

AACR: Affimed builds case for natural killer cell therapy

Phil Taylor Affimed, bispecific antibody, classical Hodgkin lymphoma, immuno-oncology, natural killer cell, non-Hodgkin lymphoma, Oncology 0 Comment

Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13

AACR: Affimed builds case for natural killer cell therapy

https://pharmaphorum.com/news/aacr-affimed-builds-case-for-natural-killer-cell-therapy/

xray image of human head with brain and electric pulses

News/ News/ R&D

Sanofi places $75m bet with ABL on popular Parkinson’s drug target

Phil Taylor ABL Bio, bispecific antibody, Parkinson's disease, partnering, Sanofi 0 Comment

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a

Sanofi places $75m bet with ABL on popular Parkinson’s drug target

https://pharmaphorum.com/news/sanofi-places-75m-bet-with-abl-on-popular-parkinsons-drug-target/

Trending

bispecific antibody

Login